RecruitingPhase 1NCT06980649
Study of BHV-1300 in Graves' Disease
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Sponsor
Biohaven Therapeutics Ltd.
Enrollment
15 participants
Start Date
Aug 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called BHV-1300 for people with graves disease. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBHV-1300
BHV-1300 is delivered subcutaneously (SC)
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06980649
Related Trials
Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
NCT074138741 location
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT0766105621 locations
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT073058189 locations
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT0768289630 locations
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323154 locations